EU clears Bristol-Myers immunotherapy drug for blood cancer

LONDON – Bristol-Myers Squibb's immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday.

Opdivo is already approved for melanoma, lung cancer and kidney cancer.